middle.news
How Will PYC’s Dose Escalation Impact ADOA Treatment Prospects?
9:28am on Wednesday 11th of June, 2025 AEST
•
Biotechnology
Read Story
How Will PYC’s Dose Escalation Impact ADOA Treatment Prospects?
9:28am on Wednesday 11th of June, 2025 AEST
Key Points
Safety Review Committee approves dose escalation from 10 to 30 micrograms per eye
PYC-001 targets Autosomal Dominant Optic Atrophy, a blinding childhood eye disease
Ongoing Phase 1 Single Ascending Dose study with plans for further clinical phases
Potential $2 billion annual market opportunity with no current treatment options
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pyc Therapeutics (ASX:PYC)
OPEN ARTICLE